Become a Member | Print Page | Sign In
News & Press: Eye Health

BREAKING: FDA Allows Expanded Beyond-Use Dates for Compounded, Repackaged Biologics

Friday, January 19, 2018  
Share |

The Food and Drug Administration finalized a new policy today that will enable ophthalmology’s continued access to sight-saving drugs like Avastin. Facilities can expand beyond-use dates for compounded or repackaged biologics, provided they perform strict, necessary quality testing. The Academy endorsed this plan last year, which was the culmination of years of our relentless advocacy work. 


The Academy led ophthalmology’s effort to preserve access to these important treatments. The American Society of Retina Specialists, Retina Society, Macula Society, American Society of Cataract and Refractive Surgery, American Glaucoma Society, Cornea Society and other medical specialty groups also played important roles in this campaign.